Research Daily Summary
Research Daily Summary: What Happened on November 10, 2026
Tu-stroma outperformed CA125 in a study of early ovarian cancer
Researchers found the blood-based RNA marker distinguished premalignant disease from controls and benign masses, but say it needs prospective testing.
Today in brief
In a study of 506 people, serum Tu-stroma distinguished a premalignant ovarian lesion from controls and benign masses better than CA125, though the authors say prospective testing is needed.1
Also published
- Peek behind the paper | Performance of microarray genotyping and massively parallel sequencing for dense SNP profiling of challenged skeletal remains BioTechniques
- Adjusting for Tumor Mutations: Q&A with Dr. Brian Corgiat Pharmaceutical Executive
- A novel candidate biomarker for detecting premalignant and early ovarian cancer Nature Medicine
- Effective Methods of Accurately Measuring Tumors Pharmaceutical Executive